The estimated Net Worth of Andrew N Schiff is at least 3.73 百万$ dollars as of 1 June 2024. Andrew Schiff owns over 4,660 units of Aclaris Therapeutics Inc stock worth over 10,817$ and over the last 10 years he sold ACRS stock worth over 3,645,748$. In addition, he makes 74,916$ as Independent Director at Aclaris Therapeutics Inc.
Andrew has made over 13 trades of the Aclaris Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 4,660 units of ACRS stock worth 5,499$ on 1 June 2024.
The largest trade he's ever made was buying 1,333,333 units of Aclaris Therapeutics Inc stock on 23 May 2014 worth over 7,999,998$. On average, Andrew trades about 84,512 units every 183 days since 2014. As of 1 June 2024 he still owns at least 9,167 units of Aclaris Therapeutics Inc stock.
You can see the complete history of Andrew Schiff stock trades at the bottom of the page.
Dr. Andrew N. Schiff M.D. serves as Independent Director of the Company. Dr. Schiff joined Aisling Capital, an investment firm, in September 1999 and currently serves as one of its managing partners. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine for six years at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of a number of private companies. Within the past five years, he served as a director of the publicly held life sciences companies ZELTIQ Aesthetics, Inc. and Agile Therapeutics, Inc. He is a longtime supporter and board member of the Visiting Nurse Service of New York, as well as other charitable organizations. Dr. Schiff received an M.D. degree from Cornell University Medical College, an M.B.A. degree from Columbia University, and a B.S. degree with honors in Neuroscience from Brown University. Our Board believes that Dr. Schiff’s medical background and venture experience qualify him to serve as a director of our company.
As the Independent Director of Aclaris Therapeutics Inc, the total compensation of Andrew Schiff at Aclaris Therapeutics Inc is 74,916$. There are 11 executives at Aclaris Therapeutics Inc getting paid more, with Neal Walker having the highest compensation of 3,150,020$.
Andrew Schiff is 54, he's been the Independent Director of Aclaris Therapeutics Inc since 2017. There are 6 older and 6 younger executives at Aclaris Therapeutics Inc. The oldest executive at Aclaris Therapeutics Inc is Maxine Gowen, 62, who is the Independent Director.
Andrew's mailing address filed with the SEC is C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087.
Over the last 9 years, insiders at Aclaris Therapeutics Inc have traded over 101,608,525$ worth of Aclaris Therapeutics Inc stock and bought 10,163,038 units worth 66,383,599$ . The most active insiders traders include Braden Michael Leonard、Capital Management, Llc Kol...、Llc Fmr. On average, Aclaris Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of 111,818$. The most recent stock trade was executed by Kevin Balthaser on 1 September 2024, trading 1,000 units of ACRS stock currently worth 1,180$.
aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
Aclaris Therapeutics Inc executives and other stock owners filed with the SEC include: